Cargando…

Successful Treatment with Lurasidone of First-Episode Psychosis in Down Syndrome: Case Report and Literature Review

INTRODUCTION: Co-morbid psychiatric disorders are common in Down syndrome (DS). Evidence is limited for pharmacotherapy, specifically antipsychotics, for psychiatric co-morbidity in DS. OBJECTIVES: To describe a case of a patient with DS who developed a first-episode psychosis (FEP) and who responde...

Descripción completa

Detalles Bibliográficos
Autor principal: Delgado Montfort, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567118/
http://dx.doi.org/10.1192/j.eurpsy.2022.2065
_version_ 1784809321808265216
author Delgado Montfort, L.
author_facet Delgado Montfort, L.
author_sort Delgado Montfort, L.
collection PubMed
description INTRODUCTION: Co-morbid psychiatric disorders are common in Down syndrome (DS). Evidence is limited for pharmacotherapy, specifically antipsychotics, for psychiatric co-morbidity in DS. OBJECTIVES: To describe a case of a patient with DS who developed a first-episode psychosis (FEP) and who responded to lurasidone in monotherapy and to review recent literature on the treatment of psychosis in patients with DS. METHODS: (1) Case report: FEP in DS patient treated with lurasidone 37 mg/day. (2) Narrative review on the treatment of psychosis in DS patients through PubMed database (1990-2020). Key terms: “psychosis”, “Down Syndrome”, “pharmacological treatment”, “antipsychotic drugs”. RESULTS: A 21-year-old woman with DS, without psychiatric history, presenting with behavioural anomalies, aggressiveness, soliloquies, and unmotivated laughs was referred to our outpatient clinic by her general practitioner. Symptoms began one year prior and progressively worsened, impairing her daily functionality. Previous blood workup was normal. She was diagnosed with FEP and began treatment with lurasidone 37 mg. At 4-week follow-up, she showed total remission of the psychotic symptoms, had no tolerability complaints, and returned to baseline functionality levels. Discussion: No reports of lurasidone use in psychosis in DS have been published. To treat psychotic symptoms in DS, most literature reports describe the use of typical antipsychotics, which are usually effective, but often poorly tolerated; atypical antipsychotics such as risperidone and aripiprazole have also been used. CONCLUSIONS: Lurasidone may be a useful option in patients with FEP in DS. Further research is warranted on treatment of psychosis in this population. DISCLOSURE: No significant relationships.
format Online
Article
Text
id pubmed-9567118
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-95671182022-10-17 Successful Treatment with Lurasidone of First-Episode Psychosis in Down Syndrome: Case Report and Literature Review Delgado Montfort, L. Eur Psychiatry Abstract INTRODUCTION: Co-morbid psychiatric disorders are common in Down syndrome (DS). Evidence is limited for pharmacotherapy, specifically antipsychotics, for psychiatric co-morbidity in DS. OBJECTIVES: To describe a case of a patient with DS who developed a first-episode psychosis (FEP) and who responded to lurasidone in monotherapy and to review recent literature on the treatment of psychosis in patients with DS. METHODS: (1) Case report: FEP in DS patient treated with lurasidone 37 mg/day. (2) Narrative review on the treatment of psychosis in DS patients through PubMed database (1990-2020). Key terms: “psychosis”, “Down Syndrome”, “pharmacological treatment”, “antipsychotic drugs”. RESULTS: A 21-year-old woman with DS, without psychiatric history, presenting with behavioural anomalies, aggressiveness, soliloquies, and unmotivated laughs was referred to our outpatient clinic by her general practitioner. Symptoms began one year prior and progressively worsened, impairing her daily functionality. Previous blood workup was normal. She was diagnosed with FEP and began treatment with lurasidone 37 mg. At 4-week follow-up, she showed total remission of the psychotic symptoms, had no tolerability complaints, and returned to baseline functionality levels. Discussion: No reports of lurasidone use in psychosis in DS have been published. To treat psychotic symptoms in DS, most literature reports describe the use of typical antipsychotics, which are usually effective, but often poorly tolerated; atypical antipsychotics such as risperidone and aripiprazole have also been used. CONCLUSIONS: Lurasidone may be a useful option in patients with FEP in DS. Further research is warranted on treatment of psychosis in this population. DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9567118/ http://dx.doi.org/10.1192/j.eurpsy.2022.2065 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Delgado Montfort, L.
Successful Treatment with Lurasidone of First-Episode Psychosis in Down Syndrome: Case Report and Literature Review
title Successful Treatment with Lurasidone of First-Episode Psychosis in Down Syndrome: Case Report and Literature Review
title_full Successful Treatment with Lurasidone of First-Episode Psychosis in Down Syndrome: Case Report and Literature Review
title_fullStr Successful Treatment with Lurasidone of First-Episode Psychosis in Down Syndrome: Case Report and Literature Review
title_full_unstemmed Successful Treatment with Lurasidone of First-Episode Psychosis in Down Syndrome: Case Report and Literature Review
title_short Successful Treatment with Lurasidone of First-Episode Psychosis in Down Syndrome: Case Report and Literature Review
title_sort successful treatment with lurasidone of first-episode psychosis in down syndrome: case report and literature review
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567118/
http://dx.doi.org/10.1192/j.eurpsy.2022.2065
work_keys_str_mv AT delgadomontfortl successfultreatmentwithlurasidoneoffirstepisodepsychosisindownsyndromecasereportandliteraturereview